Here we have used glucagon-like peptide 1 (GLP-1) as a ‘model’ injected peptide therapeutic used to treat obesity-linked type 2 diabetes, a very common chronic disease. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.